ISHLT/TTS-ID Measles Guidance for the Transplant Community
Published 24 June 2024
Measles remains an important and highly contagious disease and there are multiple outbreaks occurring in the world. Since live attenuated vaccines, such as measles, mumps, and rubella (MMR), are contraindicated in immunocompromised patients, and with no approved antiviral therapies for measles, community exposures in solid organ transplant patients can lead to life-threatening infection.
The ISHLT Infectious Diseases Professional Community, in collaboration with the Transplant Infectious Diseases Section of The Transplantation Society, have developed a document to provide guidance to all of the transplant community.
Please note that measles epidemiology continues to evolve, and the recommendations contained in this document are subject to change.
Related Guidlines
-
ISHLT Consensus Statement on Adult and Pediatric Airway Complications after Lung Transplantation
-
ISHLT Working Formulation of a Standardized Nomenclature for Cardiac Allograft Vasculopathy—2010
-
Donor Heart and Lung Procurement: A Consensus Statement
-
Generic Drug Immunosuppression in Thoracic Transplantation
-
ISHLT Consensus Statement for the Standardization of Bronchoalveolar Lavage in Lung Transplantation

